Síguenos en Twitter     Síguenos en Facebook     Síguenos en Google+     Síguenos en YouTube     Siguenos en Linkedin     Correo Grupsagessa     Gmail     Yahoo Mail     Dropbox     Instagram     Pinterest     Slack     Google Drive     Reddit     StumbleUpon     Print

SOBRE EL AUTOR **

Mi foto
FACP. Colegio de médicos de Tarragona Nº 4305520 / fgcapriles@gmail.com

WORLD EMERGENCY MEDICINE SOCIETIES

My Heart is Racing! Select Cardiac Arrhythmias and Practice Updates

Buscar en contenido

Contenido:

sábado, 12 de enero de 2013

Carvedilol


All Beta-Blockers Not Created Equal
By Todd Neale, Senior Staff Writer, MedPage Today
Published: January 11, 2013
Reviewed by F. Perry Wilson, MD, MSCE; Instructor of Medicine, Perelman School of Medicine at the University of Pennsylvania and Dorothy Caputo, MA, BSN, RN, Nurse Planner

"Action Points


  • Carvedilol is superior to other beta-1 selective beta-blockers in terms of all-cause mortality among patients with heart failure, according to this meta-analysis.
  • Be aware that the results of the meta-analysis were heavily driven by one large trial in each of the two patient subgroups examined."

Primary source: American Journal of Cardiology
Source reference:
DiNicolantonio J, et al "Meta-analysis of carvedilol versus beta 1 selective beta-blockers (atenolol, bisoprolol, metoprolol, and nebivolol" Am J Cardiol 2013; DOI: 10.1016/j.amjcard.2012.11.031.